Clinical reference Biomarker Directory
Back to directory

C8

Established

C8 is a terminal complement component; deficiency causes selective Neisseria infection susceptibility.

Also known as Complement component 8
In plain language

C8 is another building block of the terminal complement "kill switch." As with C5, C6, and C7, its absence mainly causes a specific weakness against Neisseria bacteria rather than a broad immune problem.

Biomarker & context

C8 is a membrane attack complex component of the terminal complement pathway that helps anchor and initiate pore formation in target bacterial cell membranes, working with C5, C6, C7, and C9.

What it indicates

C8 deficiency, like the other terminal components, is specifically associated with recurrent Neisseria meningitidis and gonococcal infections rather than broader infectious or autoimmune risk.

Diagnosis & clinical testing

Diagnosed via CH50/AH50 screening followed by specific terminal complement assays; genetic testing can identify the specific complement gene variant responsible.

Guiding treatment

Meningococcal vaccination, family screening (given autosomal recessive inheritance), and prompt infection treatment are standard management once C8 deficiency is confirmed.

Clinical significance

Part of the shared C5-C9 terminal pathway deficiency syndrome.

References
  1. ScienceDirect Topics. Complement Deficiency — an overview.